← Back to Search

Virus Therapy

RTX-321 for Cervical Cancer

Phase 1

Waitlist Available

Research Sponsored by Rubius Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 months

Awards & highlights

Study Summary

This trial is testing a new cancer treatment for patients with HPV 16+ cancers that have spread or returned after previous treatment.

Eligible Conditions

Cervical Cancer
Anal Cancer
Head and Neck Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicities (DLTs) of RTX-321

Safety Assessment by rate of Adverse Events

Secondary outcome measures

Anti-tumor activity of RTX-321

Pharmacodynamics (PD) of RTX-321

Pharmacokinetics (PK) of RTX-321

Trial Design

2Treatment groups

Experimental Treatment

Group I: RTX-321 Dose ExpansionExperimental Treatment1 Intervention

Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.

Group II: RTX-321 Dose EscalationExperimental Treatment1 Intervention

Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rubius TherapeuticsLead Sponsor

3 Previous Clinical Trials

77 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still being accepted for enrolment in this research trial?

"According to records hosted on clinicaltrials.gov, this trial has ceased recruiting patients since May 23rd 2022. It was first posted in April 8th 2021 and is no longer accepting applications at this time; however, 593 other studies are currently enrolling participants."

Answered by AI

Are there numerous sites conducting this clinical experiment within the city limits?

"The University of Alabama in Birmingham, the Sarah Cannon Research Institute situated in Nashville and OU Health Stephenson Cancer Center located in Oklahoma City are all partaking as trial sites for this study. Additionally, 10 other medical centres across the US have been selected to participate."

Answered by AI

Does RTX-321 pose any potential risks to human health?

"Due to the limited clinical data available, RTX-321 scored a 1 on our team's safety scale. This is in part due to it being an early Phase 1 trial and lacking evidence of efficacy or longterm safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

2021. "RTX-321 Monotherapy in Patients With HPV 16+ Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04672980.